

## Acromegaly Enrollment Form Fax Referral To: 1-888-280-1191 OR 787-759-4161

Phone: 1-888-280-1190 OR 787-759-4162

Email Referral To: Customer.ServiceFax@CVSHealth.com

Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

PATIENT INFORMAT	ION (Complete or include d		et)		
atient Name:				DOB:	
ddress:			City, State, ZIP Cod	le:	
ender: 🗌 Male 🔲 Fema	le				
referred Contact Methods	:  Phone (to primary # provident)	ded below) 🗌 Text	t (to cell # provided be	elow) 🗌 Email (to ema	il provided below)
ote: Carrier charges may appl	ly. If unable to contact via text o	r email, Specialty F	Pharmacy will attempt	to contact by phone.	
rimary Phone:			Alternate Phone: _		
<b>Minor</b> , Parent/Caregiver/	'Guardian Name (Last, First)	·		·	
elationship to minor:					
nail:		Last Four	of SSN:	Primary Language:	
PRESCRIBER INFORM	MATION				
escriber's Name:			State License #	:	
 PI #:	DEA #:	Group or Hospital:			
ldress:		C	itv. State. ZIP Code	:	
ione:	Fax	Contact Pers	son:	Contact's Pho	one:
INSTIDANCE INFORM	IATION Please fax copy of	prescription and	d incurance carde w	with this form if avails	able (front and back)
		prescription and	a ilisarance caras w	nui uno ioiin, n avait	ible (ITOTIL and back)
	NICAL INFORMATION	Obt	Detient Com	□ Oth acc	
eds by Date:		Snip to:	Patient    Office	Otner:	
agnosis (ICD-10):					
E22.0 acromegaly and p		U Other C	Code: Descr	ription:	
tient Clinical Informatio	<u>n:</u>				
ergies:		Height:	in/cm	Weight:	lb/kg
PRESCRIPTION INFO	PRMATION				
MEDICATION	STRENGTH		DOSE & DIRECTION	ONS	QUANTITY/REFILLS
Bynfezia Pen (octreotide acetate) injection	2,500 mcg/mL	☐ Administer	mca SC three time	es a dav	1 pen 2 pens
		Administer mcg SC three times a day Other:			Other:
		Guion			Refills:
Lanreotide Injection	60 mg prefilled syringe	☐ Inject 90 ma	(1 syringe) SC every 4 weeks	weeks	4-week supply
	90 mg prefilled syringe	Other: Inject mg (1 syringe) SC every 4 weeks			12-week supply
	120 mg prefilled syringe	-			Refills:
Sandostatin Injection Ampules	☐ 50 mcg/mL ☐ 100 mcg/mL	Administer mcg SC three times a day		Quantity: Refills:	
	500 mcg/mL	Other:	r:		riciniis.
Sandostatin Injection	200 mcg/mL (5 ml)	Administer	mcg SC three time	es a day	Quantity:
Iulti-dose Vials	1,000 mcg/mL (5 ml)	Other:		so a day	Refills:
	10 mg vial kit	Mix the contents of one vial with diluent and administer			4-week supply
Sandostatin LAR Depot	20 mg vial kit	intragluteally every 4 weeks Other:			12-week supply
	30 mg vial kit				Refills:
Somatuline Depot	60 mg prefilled syringe	☐ Inject 90 mg (1 syringe) SC every 4 weeks ☐ Other: Inject mg (1 syringe) SC every 4 weeks			4-week supply
	90 mg prefilled syringe				12-week supply
	120 mg prefilled syringe				Refills:
	10 mg vial				10 mg vial kits
Somavert	15 mg vial	☐ Injectmg SC once daily ☐ Other:			15 mg vial kits
	20 mg vial				20 mg vial kits
	25 mg vial				Refills:
Patient is interested in nations assessed	30 mg vial	MP SIGNATURE NOT AI	LLOWED ^	noillary supplies and kits are in	lad as pooded for administration
Patient is interested in patient suppor				IRE NOT ALLOW	ded as needed for administration
<u>o</u> PRES					
				ct Selection Permitted /	
"Dispense As Written" / Brand Med	lically Necessary / Do Not Substitute /	No Substitution /	May Substitute / Produc Substitution Permissible		

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates. ©2022 CVS Specialty and/or one of its affiliates. 75-47192A 04/06/22